Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galidesivir - BioCryst Pharmaceuticals

Next Previous
Drug Profile

Galidesivir - BioCryst Pharmaceuticals

Alternative Names: BCX-4430

Latest Information Update: 01 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albert Einstein College of Medicine; BioCryst Pharmaceuticals; Victoria University of Wellington
  • Developer BioCryst Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Utah State University
  • Class Antivirals; Purine nucleosides; Pyrimidine nucleosides; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action RNA-dependent RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued COVID 2019 infections; Ebola virus infections; Marburg virus disease; Middle East respiratory syndrome coronavirus; Yellow fever; Zika virus infection

Most Recent Events

  • 28 Feb 2023 Discontinued - Phase-I for COVID-2019 infections in Brazil (IV)
  • 28 Feb 2023 Discontinued - Phase-I for Ebola virus infections (In volunteers) in United Kingdom (IM)
  • 28 Feb 2023 Discontinued - Phase-I for Marburg virus disease (In volunteers) in United Kingdom (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top